A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.
Estimated remission and retention rates do not differ significantly among patients with rheumatoid arthritis treated with either certolizumab pegol, abatacept, or biosimilar infliximab, show the results of a surrogate randomized controlled trial.
Real-world study results suggest that mild tapering of tumor necrosis factor inhibitors does not influence the probability of achieving inactive disease among patients with axial spondyloarthritis.
Vitamin D intake is inversely associated with cartilage degeneration among patients with osteoarthritis, and supplementation may have a protective effect, suggests an analysis of data from the Osteoarthritis Initiative.
The biologic treatment era has led to “remarkable prognostic improvement,” relative to the methotrexate era, for children with juvenile idiopathic arthritis, show data reported in Arthritis Research & Therapy.
Psoriatic arthritis patients treated with biologic DMARDs have higher bone mass and strength than those not receiving DMARD treatment, suggest findings from a cross-sectional study.
In the past two decades pregnancy outcomes, including in-hospital maternal mortality, have improved among women with systemic lupus erythematosus, but further improvements are needed to reduce risks further, US research shows.
Genetic liability for rheumatoid arthritis is associated with lower IQ and symptoms of hyperactivity and inattention during childhood and adolescence, supporting a link between genetic risk for the condition and neural phenotypes, UK researchers report.
The tumor necrosis factor inhibitors adalimumab and infliximab both show good efficacy when used as first biologic agents in patients with refractory uveitis due to Behçet's disease, Spanish research shows.
Baricitinib monotherapy may be a suitable maintenance strategy for some patients with rheumatoid arthritis, but some may also need methotrexate, suggest findings from a post-hoc analysis.
Findings from a phase III trial conducted in the USA suggest that tanezumab improves pain and physical function scores relative to placebo among patients with moderate-to-severe hip or knee osteoarthritis and an inadequate response to analgesics.
People with entero-Behçet’s disease and active ulcerative lesions who are treated with tumor necrosis factor inhibitors, either alone or in combination with corticosteroids, are more likely to experience ulcer cure or improvement than those taking corticosteroids alone, researchers report.
People with osteoarthritis are significantly more likely than those without to have multiple comorbidities, particularly stroke, peptic ulcers, and the metabolic syndrome, show results of a systematic review and meta-analysis of observational data.
Glucocorticoid tapering and complete withdrawal can be achieved in patients with systemic lupus erythematosus and may be particularly successful in those with long-term remission or low disease activity, Italian researchers report.
Anxiety and depressive symptoms are associated with pain and disability but not active joint count or biomarkers of inflammation in adolescents with juvenile idiopathic arthritis, researchers report.
Secukinumab improves axial manifestations in patients with psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, primary analysis of the phase III MAXIMISE trial shows.
Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.
The anti‐nerve growth factor monoclonal antibody fasinumab improves pain and function in patients with knee or hip osteoarthritis who have a history of inadequate response or intolerance to analgesics, study findings indicate.
A randomized trial has failed to demonstrate noninferiority of ultra-low dose rituximab to a standard low dose of the drug in patients with rheumatoid arthritis.
The interleukin-1 receptor inhibitor anakinra merits further investigation for the treatment of Kawasaki disease, suggest findings from a phase IIa trial presented at the EULAR 2019 congress in Madrid, Spain.